


[Document Name] Claims

[Claim 1]

A compound having the general formula (I) shown below,



[wherein,

$R^1$  represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;

$R^2$  represents a phenyl group substituted with from 1 to 3 halogen atoms;

$R^3$  represents a phenyl group substituted with a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group, and

n represents an integer of 0 or 1).

[Claim 2]

A compound according to Claim 1, wherein  $R^1$  is 3-isopropoxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 3]

A compound according to Claim 1, wherein  $R^1$  is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 4]

A compound according to any one claim selected from Claims 1 to 3, wherein  $R^2$  is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

[Claim 5]

A compound according to any one claim selected from Claims 1 to 3, wherein  $R^2$  is 3,4-dichlorophenyl.

## [Claim 6]

A compound according to any one claim selected from Claims 1 to 5, wherein D is an oxygen atom.

## [Claim 7]

A compound according to any one claim selected from Claims 1 to 6, wherein n is 0.

## [Claim 8]

A compound according to Claim 1, wherein R<sup>1</sup> is 3-isopropoxy, D is a methylene group, and n is 1.

## [Claim 9]

A compound according to any one claim selected from Claims 1 to 8, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

## [Claim 10]

A compound according to Claim 1, wherein said compound is any one of the compounds listed below:

- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,

- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.



[Claim 11]

A compound according to Claim 1, wherein said compound is any one of the compounds listed below:

- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate, and
- 2-[1-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

[Claim 12]

A compound, having an enantiomeric excess which is substantially 100%, having the general formula (I') or (I'') shown below,



(wherein

$R^1$  represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;

$R^2$  represents a phenyl group substituted with from 1 to 3 halogen atoms;

$R^3$  represents a phenyl group substituted with a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group; and  
n represents an integer of 0 or 1).

[Claim 13]

A compound according to Claim 12, wherein R<sup>1</sup> is 3-isopropoxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 14]

A compound according to Claim 12, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 15]

A compound according to any one claim selected from Claims 12 to 14, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

[Claim 16]

A compound according to any one claim selected from Claims 12 to 14, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

[Claim 17]

A compound according to any one claim selected from Claims 12 to 16, wherein D is an oxygen atom.

[Claim 18]

A compound according to any one claim selected from Claims 12 to 17, wherein n is 0.

[Claim 19]

A compound according to Claim 12, wherein R<sup>1</sup> is 3-isopropoxy, D is a methylene group, and n is 1.

[Claim 20]

A compound according to any one claim selected from Claims 12 to 19, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

[Claim 21]

A compound according to any one claim selected from Claims 12 to 20, having the general formula (I').

[Claim 22]

A compound according to Claim 12, wherein said compound is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.

[Claim 23]



A compound according to Claim 12, wherein said compound is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-[3,5-bis(trifluoromethyl)benzoyl]-1-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and

- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

[Claim 24]

A method for obtaining a compound, having an enantiomeric excess which is substantially 100%, having the general formula (I') or (I'') by crystallizing a mixture of a compound having the general formula (I') and a compound having the general formula (I''):



(in the general formulae (I') and (I''),

$R^1$  represents a phenyl group substituted with 1 to 3 groups selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;

$R^2$  represents a phenyl group substituted with 1 to 3 halogen atoms;

$R^3$  represents a  $C_1$ - $C_4$  alkyl group, a phenyl group, or a phenyl group substituted with a  $C_1$ - $C_4$  alkyl group, a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group; and

n represents an integer of 0 or 1).

[Claim 25]

A method according to Claim 24, wherein  $R^1$  is 3-isopropoxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 26]



A method according to Claim 24, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 27]

A method according to any one claim selected from Claims 24 to 26, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

[Claim 28]

A method according to any one claim selected from Claims 24 to 26, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

[Claim 29]

A method according to any one claim selected from Claims 24 to 28, wherein R<sup>3</sup> is a methyl group, a phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

[Claim 30]

A method according to any one claim selected from Claims 24 to 29, wherein D is an oxygen atom.

[Claim 31]

A method according to any one claim selected from Claims 24 to 30, wherein n is 0.

[Claim 32]

A method according to Claim 24, wherein R<sup>1</sup> is 3-isopropoxyphenyl, D is a methylene group, and n is 1.

[Claim 33]

A method according to any one claim selected from Claims 24 to 32, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

[Claim 34]

A method according to any one claim selected from Claims 24 to 33, for obtaining a compound, having an enantiomeric excess which is substantially 100%, having the general formula (I').

[Claim 35]

A method according to Claim 24, for obtaining any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-{{3,5-bis(trifluoromethyl)phenyl}acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{{3,5-bis(trifluoromethyl)phenyl}acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{{3,5-bis(trifluoromethyl)phenyl}acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate, and
- (+)-2-[1-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate.

[Claim 36]


A method according to Claim 24, for obtaining any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,


- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

[Claim 37]


A method for preparing compounds having general formula (III) shown below or pharmaceutically acceptable salts thereof, which is characterized by reacting a compound having general formula (I') shown below with a compound having general formula (II) shown below:



(wherein  $R^1$  represents a phenyl group substituted with 1 to 3 substituents selected from a group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;  $R^2$  represents a phenyl group substituted with 1 to 3 halogen atoms;  $R^3$  represents a phenyl group or a phenyl group substituted with a  $C_1$ - $C_4$  alkyl group, a halogen atom or a nitro group; D represents an oxygen atom or a methylene group; and n represents an integer of 0 or 1),



(wherein G represents a  $>C-OH$  group or a  $>S \rightarrow O$  group),  
and



(wherein D, G, R<sup>1</sup>, R<sup>2</sup> and n have the same meanings as those indicated hereinbefore).

[Claim 38]

A method according to Claim 37, wherein R<sup>1</sup> is 3-isopropoxyphenyl, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 39]

A method according to Claim 37, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

[Claim 40]

A method according to any one claim selected from Claims 37 to 39, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

[Claim 41]

A method according to any one claim selected from Claims 37 to 39, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

[Claim 42]

A method according to any one claim selected from Claims 37 to 41, wherein R<sup>3</sup> is a phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

[Claim 43]

A method according to any one claim selected from Claims 37 to 42, wherein D is an oxygen atom.

## [Claim 44]

A method according to any one claim selected from Claims 37 to 43, wherein n is 0.

## [Claim 45]

A method according to Claim 37, wherein R<sup>1</sup> is 3-isopropoxyphenyl, D is a methylene group, and n is 1.

## [Claim 46]

A method according to any one claim selected from Claims 37 to 45, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

## [Claim 47]

A method according to Claim 37, wherein the compound having general formula (I') is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,

- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-{{[3,5-bis(trifluoromethyl)phenyl]acetyl}}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,

- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate.

[Claim 48]

A method according to Claim 37, wherein the compound having general formula (I') is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.